VC
ZBIO

Vivo Capital’s Zenas BioPharma ZBIO Stock Holding History

Vivo Capital’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-853,495
Closed -$31M – 55
2025
Q4 		$31M Sell
853,495
-329,765
-28% -$10.8M 2% 17
2025
Q3 		$26.3M Hold
1,183,260
– – 2.11% 16
2025
Q2 		$11.5M Hold
1,183,260
– – 1.17% 15
2025
Q1 		$9.35M Hold
1,183,260
– – 1.24% 15
2024
Q4 		$9.69M Hold
1,183,260
– – 1.09% 21
2024
Q3 		$20M Buy
+1,183,260
New +$21.3M 1.66% 12

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Vivo Capital's ZBIO Position: Q1 2026 in Review

Vivo Capital sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 853,495 shares — an estimated $31M sold.

Vivo Capital first reported a position in ZBIO in Q3 2024 and held it in 6 quarters. The position peaked at $31M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Vivo Capital reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
  • Vivo Capital sold 853,495 Zenas BioPharma shares in Q1 2026, an estimated $31M.
  • Vivo Capital first reported a position in Zenas BioPharma in Q3 2024 and held it in 6 quarters.
  • Vivo Capital's Zenas BioPharma position peaked at $31M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.